$HIMS
Hims & Hers Health, Inc.

2019 Q3 Form 10-Q Financial Statement

#000119312519290077 Filed on November 12, 2019

View on sec.gov

Income Statement

Concept 2019 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $450.0K
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $450.0K
YoY Change
Operating Profit -$449.9K
YoY Change
Interest Expense $890.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net $886.0K
YoY Change
Pretax Income $440.0K
YoY Change
Income Tax
% Of Pretax Income
Net Earnings $436.0K
YoY Change
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $17.49K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.800M
YoY Change
Cash & Equivalents $1.782M
Short-Term Investments
Other Short-Term Assets $200.0K
YoY Change
Inventory
Prepaid Expenses $177.4K
Receivables
Other Receivables
Total Short-Term Assets $1.959M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $202.1M
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $202.1M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $1.959M
Total Long-Term Assets $202.1M
Total Assets $204.1M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $475.6K
YoY Change
Accrued Expenses $474.7K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $100.0K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.037M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $7.200M
YoY Change
Total Long-Term Liabilities $7.200M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.037M
Total Long-Term Liabilities $7.200M
Total Liabilities $8.231M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings $419.4K
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.000M
YoY Change
Total Liabilities & Shareholders Equity $204.1M
YoY Change

Cashflow Statement

Concept 2019 Q3
OPERATING ACTIVITIES
Net Income $436.0K
YoY Change
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$210.0K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$201.3M
YoY Change
Cash From Investing Activities -$201.3M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 203.2M
YoY Change
NET CHANGE
Cash From Operating Activities -210.0K
Cash From Investing Activities -201.3M
Cash From Financing Activities 203.2M
Net Change In Cash 1.780M
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$210.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
436045
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
466544
CY2019Q3 oacu Business Combination Covenants To Proceed With Business Combination
BusinessCombinationCovenantsToProceedWithBusinessCombination
In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and a majority of the shares voted are voted in favor of the Business Combination.
CY2019Q3 us-gaap Assets
Assets
204094833
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
474696
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
475612
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1036867
CY2019Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4579960
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
419439
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
5000006
CY2019Q3 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.00
CY2019Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2019Q2 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
25000
CY2019Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
11800000
oacu Common Stock Shares Resale Or Transfer Share Price Threshold
CommonStockSharesResaleOrTransferSharePriceThreshold
12.00
oacu Advances From Related Party Agreed Amount
AdvancesFromRelatedPartyAgreedAmount
300000000
CY2019Q3 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
10000
dei Document Type
DocumentType
10-Q
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Document Period End Date
DocumentPeriodEndDate
2019-09-30
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Registrant Name
EntityRegistrantName
Oaktree Acquisition Corp.
dei Entity Central Index Key
EntityCentralIndexKey
0001773751
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019Q2 oacu Percentage Of Founder Shares On Outstanding Shares
PercentageOfFounderSharesOnOutstandingShares
0.20
CY2019Q3 oacu Business Combination Requisites To Be Satisfied
BusinessCombinationRequisitesToBeSatisfied
The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the assets held in the Trust Account (excluding the deferred underwriting commissions and taxes payable on income earned on the Trust Account) at the time of the signing of the agreement to enter into the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act.
CY2019Q3 oacu Description Of Results For Non Compliance With Business Combination
DescriptionOfResultsForNonComplianceWithBusinessCombination
The Company’s Sponsor, officers and directors (the “initial shareholders”) have agreed not to propose an amendment to the Amended and Restated Memorandum and Articles of Association (a) that would modify the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if the Company does not complete a Business Combination within 24 months from the closing of the Initial Public Offering, or July 22, 2021
CY2019Q3 oacu Investment Securities Maturity Period
InvestmentSecuritiesMaturityPeriod
P185D
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div><div style="text-indent: 3%; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; background: none; text-align: justify;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; background: none;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Use of Estimates </div></div></div><div style="text-indent: 3%; font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; background: none; text-align: justify;"><div style="background: none; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the unaudited condensed financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting periods. Making estimates requires management to exercise significant judgment.&#160;It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future conforming events.&#160;Accordingly, the actual results could differ from those estimates. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
oacu Common Stock Conversion Description
CommonStockConversionDescription
20%&#160;of the sum of (i)&#160;the total number of Class&#160;A ordinary shares issued and outstanding upon completion of the Initial Public Offering, plus (ii)&#160;the total number of Class&#160;A ordinary shares issued or deemed issued or issuable upon conversion or exercise of any equity-&#160;linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination, excluding any Class&#160;A ordinary shares or equity-linked securities exercisable for or convertible into Class&#160;A ordinary shares issued, or to be issued, to any seller in the initial Business Combination and any Private Placement Warrants issued to the Sponsor upon conversion of Working Capital Loans.
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
true
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
204094833
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1781500
CY2019Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
177350
CY2019Q3 us-gaap Assets Current
AssetsCurrent
1958850
CY2019Q3 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
202135983
CY2019Q3 oacu Accrued Expensed Related Party Current
AccruedExpensedRelatedPartyCurrent
24839
CY2019Q3 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
61720
CY2019Q3 oacu Deferred Underwriting Commissions
DeferredUnderwritingCommissions
7043750
CY2019Q3 us-gaap Liabilities
Liabilities
8230617
CY2019Q3 us-gaap Redeemable Noncontrolling Interest Equity Common Carrying Amount
RedeemableNoncontrollingInterestEquityCommonCarryingAmount
190864210
CY2019Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q3 oacu Deferred Legal Fees Non Current
DeferredLegalFeesNonCurrent
150000
CY2019Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2019Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
449938
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-449938
us-gaap Operating Income Loss
OperatingIncomeLoss
-466544
CY2019Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
885983
us-gaap Investment Income Interest
InvestmentIncomeInterest
885983
us-gaap Net Income Loss
NetIncomeLoss
419439
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
0
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25000
oacu Increase Decrease In Accrued Expensed Related Party
IncreaseDecreaseInAccruedExpensedRelatedParty
-24839
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-207200
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-16606
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
201250000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-201250000
oacu Proceeds From Issuance Of Capital Units
ProceedsFromIssuanceOfCapitalUnits
201250000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
8394
CY2019Q3 oacu Capital Units Value Of Shares Issued During Period
CapitalUnitsValueOfSharesIssuedDuringPeriod
201250000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
11855223
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
6025000
CY2019Q3 us-gaap Temporary Equity Issue Period Increase Or Decrease
TemporaryEquityIssuePeriodIncreaseOrDecrease
-190864210
us-gaap Investment Income Interest
InvestmentIncomeInterest
885983
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
177350
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
361200
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
50655
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
6025000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
4036300
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
203238700
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0
CY2019Q3 oacu Offering Costs Included In Accrued Expenses
OfferingCostsIncludedInAccruedExpenses
-113496
CY2019Q3 oacu Offering Costs Included In Accounts Payable
OfferingCostsIncludedInAccountsPayable
-424957
CY2019Q3 oacu Offering Costs Included In Notes Payable Related Party
OfferingCostsIncludedInNotesPayableRelatedParty
61720
CY2019Q3 oacu Deferred Underwriting Commissions Recognized In Ipo
DeferredUnderwritingCommissionsRecognizedInIpo
7043750
CY2019Q3 oacu Deferred Legal Fees Recognized In Ipo
DeferredLegalFeesRecognizedInIpo
150000
CY2019Q3 oacu Offering Costs Paid By Sponsor In Exchange For Issuance Of Classb Ordinary Shares
OfferingCostsPaidBySponsorInExchangeForIssuanceOfClassbOrdinaryShares
-25000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1781500
CY2019Q3 us-gaap Cash
Cash
1800000
oacu Proceeds From Issuance Of Founder Shares
ProceedsFromIssuanceOfFounderShares
25000
CY2019Q3 oacu Advances From Related Party
AdvancesFromRelatedParty
62000
CY2019Q3 oacu Working Capital
WorkingCapital
922000
CY2019Q3 oacu Working Capital Loan
WorkingCapitalLoan
0

Files In Submission

Name View Source Status
0001193125-19-290077-index-headers.html Edgar Link pending
0001193125-19-290077-index.html Edgar Link pending
0001193125-19-290077.txt Edgar Link pending
0001193125-19-290077-xbrl.zip Edgar Link pending
d828949d10q.htm Edgar Link pending
d828949dex311.htm Edgar Link pending
d828949dex312.htm Edgar Link pending
d828949dex321.htm Edgar Link pending
d828949dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
oacu-20190930.xml Edgar Link completed
oacu-20190930.xsd Edgar Link pending
oacu-20190930_cal.xml Edgar Link unprocessable
oacu-20190930_def.xml Edgar Link unprocessable
oacu-20190930_lab.xml Edgar Link unprocessable
oacu-20190930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending